A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients

Clinical Pharmacology and Therapeutics

Volumn 69, Issue 4, 2001, Pages 210-222

  Mould, Diane ^a   Chapelsky, Martha ^a   Aluri, Jagadeesh ^a   Swagzdis, James ^a   Samuels, Robert ^a   Granett, Jeffrey ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CREATININE; FIBRINOGEN RECEPTOR ANTAGONIST; LOTRAFIBAN; PLACEBO;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART INFARCTION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STEADY STATE; STROKE; THROMBOCYTE AGGREGATION; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS;

ADULT; AGE FACTORS; AGED; BENZODIAZEPINES; CREATININE; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEART DISEASES; HEMORRHAGE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PIPERIDINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SEX FACTORS;

EID: 0035035790     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.114925     Document Type: Article

References (22)

1. Platelet-surface interactions
2. The pathogenesis of coronary artery disease and acute coronary syndromes
3. Collaborative overview of randomised trials of antiplatelet therapy-I prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients
4. Collaborative overview of randomised trials of antiplatelet therapy-I prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients
5. Collaborative overview of randomised trials of antiplatelet therapy-I prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients
6. A Randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
7. Characterization of a functional thrombin receptor: Issues and opportunities
8. Platelets and thrombolytic therapy
9. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine
10. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty
11. Intervention with antibody against platelet glycoprotein IIb/IIIa for reduction of clinical restenosis: Results at six months
12. Effect of the glycoprotein IIb/IIIa receptor inhibitor ABCIXIMAB with lower heparin dosages on ischemic complications of percutaneous coronary revascularization
13. Dose-finding, safety, and tolerability of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease
14. Dose-finding, safety, and tolerability of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary of cerebral atherosclerotic disease
15. Use of LC-MS/MS to cross validate a radioimmunoassay for the fibrinogen receptor antagonist, Aggrostat (tirofiban hydrochloride) in human plasma
16. Bayesian individualization of pharmacokinetics: Simple implementation and comparison with non-Bayesian methods
17. Prediction of creatinine clearance from serum creatinine
18. Analysis of nonrandomly censored ordered categorical longitudinal data from analgesic trials
19. Regression models for ordinal data
20. Population pharmacodynamic model for keterolac analgesia